Analysis of the therapeutic benefits of symptomatic slow acting drugs in osteoarthritis: emphasis on structural-modifying action
Open Access
- 16 December 2021
- journal article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 15 (6), 117-123
- https://doi.org/10.14412/1996-7012-2021-6-117-123
Abstract
The review presents an analysis of the therapeutic effect in osteoarthritis (OA) of the original complex injectable drug Alflutop (bioactive concentrate of small marine fish), which is one of the most widely used symptomatic slow acting drugs (SYSADOA) in Russia. It stimulates the proliferation of chondrocytes, activates the synthesis of the extracellular matrix by modulating transforming growth factor β (TGFβ), inhibits hyaluronidase, oxidative stress and the activity of extracellular expression of proinflammatory cytokine genes – interleukin (IL) 1β, IL6 and IL8 in vitro.The results of prospective clinical studies are presented, which demonstrate the ability of Alflutop to slow down the X-ray progression of OA of the knee joints (inhibit the narrowing of the joint space, the growth of osteophytes and increase the intra-articular concentration of hyaluronic acid), as well as restore the mobility of the hip joints when it is locally introduced into the zone of pathological changes in the articular lip of the acetabulum. Combined therapy with Alflutop leads to activation of reparative processes and significant clinical improvement in patients with post-traumatic OA, and also slows down the progression of chondrodegeneration according to magnetic resonance imaging. The new Alflutop administration regimen for knee OA (2 ml every other day, №10) can increase patient adherence to therapy.The results of clinical studies presented in the review prove the structural-modifying effect of Alflutop in OA of various localization and substantiate its widespread use in this disease in rheumatological, traumatological and orthopedic practice.Keywords
This publication has 25 references indexed in Scilit:
- Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)Aging Clinical and Experimental Research, 2017
- Knee osteoarthritis has doubled in prevalence since the mid-20th centuryProceedings of the National Academy of Sciences of the United States of America, 2017
- Peripheral Nerve Fibers and Their Neurotransmitters in Osteoarthritis PathologyInternational Journal of Molecular Sciences, 2017
- Osteoarthritis: Key elements in its pathogenesis and current agents for pathogenetic therapyModern Rheumatology Journal, 2017
- RADIOLOGICAL PROGRESSION OF KNEE OSTEOARTHRITIS ON THE BACKGROUND OF PROLONGED TREATMENT WITH ALFLUTOP (5 YEAR FOLLOW-UP)Medical Council, 2017
- Association Between Overweight and Obesity and Risk of Clinically Diagnosed Knee, Hip, and Hand Osteoarthritis: A Population‐Based Cohort StudyArthritis & Rheumatology, 2016
- RADIOLOGIC DIAGNOSTICS OF OSTEOARTHRITISDiagnostic radiology and radiotherapy, 2016
- A MULTICENTER, BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFET OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHRITIS. REPORT 2: THE ASSESSMENT OF THE STRUCTURE-MODIFYING EFFECT OF THE DRUGRheumatology Science and Practice, 2014
- OARSI guidelines for the non-surgical management of knee osteoarthritisOsteoarthritis and Cartilage, 2014
- MULTICENTER DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF THE SYMPTOM- AND STRUCTURE-MODIFYING EFFECT OF ALFLUTOP IN PATIENTS WITH KNEE OSTEOARTHROSIS. COMMUNICATION 1. EVALUATION OF THE SYMPTOM-MODIFYING EFFECT OF THE DRUGRheumatology Science and Practice, 2013